These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26494820)

  • 1. Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680-1686.
    Ou HY; Karnchanasorn R; Chuang LM; Chiu KC
    Diabetes Care; 2015 Nov; 38(11):e198. PubMed ID: 26494820
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680-1686.
    Dhatariya K
    Diabetes Care; 2016 Jan; 39(1):e18. PubMed ID: 26696665
    [No Abstract]   [Full Text] [Related]  

  • 3. Response to Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680-1686.
    Erondu N; Desai M; Ways K; Meininger G
    Diabetes Care; 2016 Jan; 39(1):e19. PubMed ID: 26696666
    [No Abstract]   [Full Text] [Related]  

  • 4. Diabetic ketoacidosis associated to canagliflozin in type 2 diabetes.
    González Sanchidrián S; Gómez-Martino Arroyo JR; Labrador Gómez PJ
    Med Clin (Barc); 2017 Feb; 148(4):e19-e20. PubMed ID: 28041622
    [No Abstract]   [Full Text] [Related]  

  • 5. Euglycemic diabetic ketoacidosis with canagliflozin: Not-so-sweet but avoidable complication of sodium-glucose cotransporter-2 inhibitor use.
    Clement M; Senior P
    Can Fam Physician; 2016 Sep; 62(9):725-8. PubMed ID: 27629668
    [No Abstract]   [Full Text] [Related]  

  • 6. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.
    Erondu N; Desai M; Ways K; Meininger G
    Diabetes Care; 2015 Sep; 38(9):1680-6. PubMed ID: 26203064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gliflozins: ketoacidosis.
    Prescrire Int; 2016 Mar; 25(169):68. PubMed ID: 27152399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin.
    Adachi J; Inaba Y; Maki C
    Intern Med; 2017; 56(2):187-190. PubMed ID: 28090050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose Cotransporter 2 Inhibitor-induced Diabetic Ketoacidosis in a Type 2 Diabetic Patient.
    Ramirez Tello EM; Orellana-Barrios MA; Nugent K
    Am J Med Sci; 2016 Jun; 351(6):634-5. PubMed ID: 27238930
    [No Abstract]   [Full Text] [Related]  

  • 10. Euglycemic diabetic ketoacidosis in type 2 diabetes treated with a sodium-glucose cotransporter-2 inhibitor.
    Jazi M; Porfiris G
    Can Fam Physician; 2016 Sep; 62(9):722-4. PubMed ID: 27629667
    [No Abstract]   [Full Text] [Related]  

  • 11. [Severe diabetic ketoacidosis, acute kidney injury and dehydration due to canagliflozin in type 2 diabetes mellitus patient: Atypical clinical presentation].
    Moreno Obregón F; Espino Montoro A; Marín Martín J; León Jiménez D
    Aten Primaria; 2019 Dec; 51(10):664-666. PubMed ID: 31326123
    [No Abstract]   [Full Text] [Related]  

  • 12. Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis.
    Bloomgarden ZT
    J Diabetes; 2016 Mar; 8(2):175-6. PubMed ID: 26611882
    [No Abstract]   [Full Text] [Related]  

  • 13. [Diabetic ketoacidosis with mild hyperglycemia associated with the use of canagliflozin. Report of one case with type 1 diabetes].
    Novik A V; García B C; Oliva I D
    Rev Med Chil; 2017 Mar; 145(3):393-396. PubMed ID: 28548198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-glucose cotransporter 2 inhibitor-associated diabetic ketoacidosis: Report of two cases with hyperglycemic ketoacidosis in type 1 diabetes.
    Harati H; Sharma V; Motazedi A
    J Diabetes; 2016 Jan; 8(1):165. PubMed ID: 26211700
    [No Abstract]   [Full Text] [Related]  

  • 15. Canagliflozin use in Type I diabetes mellitus.
    Guthrie R
    Postgrad Med; 2017 Apr; 129(3):336-339. PubMed ID: 27918226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canagliflozin induced diabetic ketoacidosis.
    Diéguez-Felechosa M; Suárez-Gutiérrez L
    Endocrinol Nutr; 2016 Oct; 63(8):430-1. PubMed ID: 27346596
    [No Abstract]   [Full Text] [Related]  

  • 17. ‘Euglycemic’ Ketoacidosis in a Patient With Type 2 Diabetes Being Treated With Canagliflozin.
    Danford C; Chan P; Magill SB
    WMJ; 2016 Aug; 115(4):206-9. PubMed ID: 29099159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible association between diabetic ketoacidosis and use of sodium-glucose co-transporter 2 inhibitor in a 17-year-old youth with type 2 diabetes.
    Shamchuk A; Doulla M; Jetha M
    CMAJ; 2021 Sep; 193(35):E1385-E1388. PubMed ID: 34493565
    [No Abstract]   [Full Text] [Related]  

  • 19. SGLT2 Inhibitors and Euglycemic Ketoacidosis.
    Masuta P; Johri G; Paul M
    Am J Ther; 2018; 25(4):e498-e500. PubMed ID: 28537992
    [No Abstract]   [Full Text] [Related]  

  • 20. Euglycemic Ketoacidosis With Sodium-Glucose Cotransporter-2 Inhibitor.
    Koch RA; Clark RF
    Am J Ther; 2018; 25(5):e590-e591. PubMed ID: 28452848
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.